Full Press Release Details
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases.
BIIB
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases
Key Takeaway: New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis